Wird geladen...
Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development
BACKGROUND: Antineoplastic therapy with the tyrosine kinase inhibitor pazopanib in patients with advanced/metastatic renal cell carcinoma (mRCC) has been associated with hypertension (HTN), cardiomyopathy, and cardiac dysrhythmias. We therefore assessed the cardiovascular (CV) risk with pazopanib in...
Gespeichert in:
| Veröffentlicht in: | Cardiooncology |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BioMed Central
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5828231/ https://ncbi.nlm.nih.gov/pubmed/29497565 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40959-017-0024-8 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|